Regeneron Q3 Revenue Rises 36%, Non-GAAP EPS Gains 70%
Regeneron reported Q3 2026 total revenue up 36% year over year and non-GAAP EPS up 70%, citing Dupixent, EYLEA HD, Libtayo and higher Sanofi collaboration revenue after repayment of the Development Balance.